1. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
2. Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
3. Shum, Y. Y.; Huang, H.; Walter, G. A.; Black, A. E.; Sekerke, C. S.; Homan, R.; Newton, R. S.; Nordblom, G. S.; Wright, D. S.; Chang, T.; Whitfield, L. R. Pharm. Res.1993,10 (Suppl) S415 (Abstract PPDM 8467).
4. Hayes, R.; Minser, D.; Jersey, J. A.; Lilley, B. E. Pharm. Res.1996,13 (Suppl) S47 (Abstract APQ 1180).
5. Yang, B. B.; Smithers, J. A.; Stern, R. H.; Sedman, A. J.; Olson, S. C. Pharm. Res.1996,13, (Suppl) S437 (Abstract PPDM 8177).